Framycetin Sulfate
An aminoglycoside antibiotic with similar characteristics and actions as neomycin.
Used topically at 1% in skin infections and 0.5% in ear and eye infections.
Given its practically zero intestinal absorption, it has been used orally for selective intestinal decontamination, preoperatively or in intensive care patients.
Since the last update we have not found published data on its excretion in breast milk.
he small dose and poor plasma absorption of most topical preparations (dermatological or otological) make it very unlikely that significant amounts will transfer into breastmilk, although following subconjunctival injection plasma levels of 5 micrograms/ml have been observed, similar to those obtained following intramuscular injection (Bron 1970).
The small dose and low plasma absorption of most topical preparations make it unlikely that a significant amount will transfer into breastmilk. In addition, its zero or very low oral bioavailability would make it difficult for it to transfer to infant plasma from ingested breast milk, except in premature infants and the immediate neonatal period when there may be greater intestinal permeability.
Alternatives
We do not have alternatives for Framycetin Sulfate since it is relatively safe.
Very Low Risk
Compatible. Not risky for breastfeeding or infant.
Low Risk
Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.
High Risk
Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.
Very High Risk
Not recommended. Cessation of breastfeeding or alternative.
Synonyms
- Neomycin B Sulphate
Writings
- Φραμυσετίνη Θειϊκή (Greek)
- Фрамицетина Сульфат (Cyrillic)
- フラミセチンスルファート (Japanese)
- Framycétine sulfate (French)
- C23H46N6O13,xH2SO4 (Molecular formula)
- 2-Deoxy-4-O-(2,6-diamino-2,6-dideoxy-α-d-glucopyranosyl)-5-O-[3-O-(2,6-diamino-2,6-dideoxy-β-l-idopyranosyl)-β-d-ribofuranosyl]streptamine sulphate (Chemical name)
- D09AA01 (ATC Code/s)
- S01AA07 (ATC Code/s)
- S02AA (ATC Code/s)
References
- Bron AJ, Richards AB, Knight-Jones D, Easty DL, Ainslie D. Systemic absorption of Soframycin after subconjunctival injection. Br J Ophthalmol. 1970Abstract Full text (link to original source)